

08 Dec 2025

Price Band

₹ 438 – ₹ 460

Issue Size

₹ 871.05 Cr

Issue Open Date

10 Dec 25

Issue Close Date

12 Dec 25

Promoters (Pre IPO)

72.93%

Promoters (Post IPO)

61.20%

Min Bid Lot Size

32 Shares

Sector

Healthcare

Other Issue Details

Fresh Issue:

₹ 353.40 Cr

Offer for Sale:

₹ 517.64 Cr

Face Value:

₹ 2/Share

Listing At:

NSE, BSE

Retail Reservation:

35.00%

Objective of the Issue

- Funding Capital Expenditure.
- Repayment / prepayment of certain outstanding borrowing.
- General corporate purposes.

Tentative Schedule

Stages	As on or Around date
Finalization of Basis of Allotment	15 December 2025
Refunds/Unblocking ASBA Fund	16 December 2025
Credit of equity shares to DP A/c	16 December 2025
Listing Date	17 December 2025

Company Profile:

- **Business:** Nephrocare Health Services Limited, incorporated in 2010, provides end-to-end dialysis care through a wide network of clinics across India and select international markets. The company offers services including diagnosis, haemodialysis, home and mobile dialysis, and wellness programs, supported by an in-house pharmacy.
- **Network:** Nephrocare operated 519 clinics with 51 across the Philippines, Uzbekistan, and Nepal. This includes the world's largest dialysis clinic in Uzbekistan. In India, the company had a presence across 288 cities in 21 States and 4 Union Territories. The company has 5,562 dialysis machines.

Management - Experienced Promoters | Board & Senior Team | Marquee Investors

Vikram Vuppala

Chairman & MD

Rohit Singh

C.E.O.

Prashant Goenka

C.F.O.

Kishore Kathri

Company Secretary

Nephrocare Health Services Limited

Financial Snapshot

Financials (INR Cr)	As on Sep 30, 2025	FY25	FY24	FY23
Equity Share Capital	3.62	1.77	1.75	1.74
Net worth	716.06	594.21	423.55	384.73
Revenue from Op.	473.50	755.81	566.16	437.30
EBITDA	110.31	166.64	99.66	48.60
EBITDA Margin (%)	23.30	22.05	17.60	11.11
Net Profit	14.23	67.10	35.13	(11.79)
EPS (Rs.)	1.69^	8.28	4.55	(1.53)
Net Asset Value (Rs.)	71.62	59.56	50.20	49.23
ROCE (%)	11.99^	18.67	10.00	0.44

Growth

The company's Revenue increase and stood at Rs 755.8 crore versus Rs 566.1 crore YoY and reported CAGR of 20.01 percent between FY23 to FY25

Margins

In FY25, Company's EBITDA increased and EBITDA margin increased by 445 basis points and stood at 22.05 percent versus 17.60 percent on YoY basis.

Multiple

During FY25, Net Asset Value of the company reported at 59.5 versus 50.2 in FY24. ROCE of the company recorded as 18.67 percent versus 10.00 percent YOY.

Business Products

- The company's core services focus on delivering comprehensive dialysis care through multiple modalities. Its main offering is in-centre haemodialysis, provided across a wide clinic network that follows standardized clinical protocols for consistent quality. It also supports ongoing treatment with related services such as diagnostics and an in-house pharmacy.
- Beyond traditional centres, the company offers flexible dialysis models to meet diverse patient needs. These include home haemodialysis, mobile or on-call dialysis, and holiday or travel dialysis, allowing patients to continue treatment conveniently and seamlessly wherever they are.
- The company delivers dialysis care that is accessible, scalable, and patient-centric. Its broad range of services enables it to reach a wide population, including smaller towns, while providing convenience, flexibility, and consistent continuity of care.

SWOT Analysis

STRENGTH

- India's and Asia's largest dialysis chain with leadership across the market.
- Driving clinical excellence and quality through protocols and adv. technology.
- Patient-centric leadership and seasoned management team.



WEAKNESS

- Losses incurred by subsidiary for three consecutive years pose a financial risk to the company.
- Dependence on healthcare professionals risks disruption if they unable to retain or attract.

OPPORTUNITIES

- Expand further in South-East Asia, while operations in existing international markets.
- Focus on innovation-led digital healthcare to enhance convenience, efficiency and reach.
- Retaining and attracting skilled and experienced doctors and clinicians.

THREATS

- Strong competitive pressure from the industry peers.
- Due to capital-intensive model, high operating cost may hamper its financials.
- Maintaining consistent quality standards across large clinic network is challenging.

Concluding Remarks

- For the last three fiscal years, the company reported a weighted average EPS of 5.40 and an weighted average RoNW of 8.99 percent. Based on its annualized FY25 earnings, the P/E stood at 55.5 with the consideration of its upper price band.
- We recommend to subscribe this IPO with medium to long term view. The company provides comprehensive dialysis care both locally and globally. It reported healthy growth across its headline numbers and its operating metrics. NHSL is well-positioned for sustained expansion, backed by its strong regional and overseas market dominance and stable recurring revenue streams.**



B-Wing, Siddhivinayak Towers,

Nr D.A.V School, Next to Kataria House, Off S.G. Highway, Makarba, Ahmedabad – 380051

DISCLAIMER

This document is for private circulation and information purposes only and should not be regarded as an investment, taxation or legal advice. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this publication and should understand that statements regarding future prospects may not be realized. In no circumstances it be used or considered as an offer to sale or a solicitation of any offer to buy or sell the securities mentioned in it. We and our affiliates, officers, directors and employees including persons involved in the preparation or issuance of this material may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender or borrower to such company or have other potential conflict of interest with respect to any recommendation and related information and opinions. The information contained in this publication may have been taken from trade and statistical services and other sources, which we believe are reliable. Kunvarji does not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinion expressed reflects judgments at this date and are subject to change without notice. Caution: Risk of loss in trading in can be substantial. You should carefully consider whether trading is appropriate for you in light of your experience, objectives, financial resources and other relevant circumstances. For more information on Research, mail us at: research@kunvarji.com